EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Management of Severe Infections

Federico Perez, Nadim G El Chakhtoura, Robert A Bonomo

Medical Clinics of North America · 2025-05 · 109 (3) · 735-747

DOI: 10.1016/j.mcna.2025.01.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Clinics of North America, 2025-05. Verfasst von Federico Perez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Geriatrics Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, OH, USA; Department of Medicine,…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Negative Bacterial Infections, Drug Resistance, Multiple, Bacterial, Carbapenems. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article provides an overview of the mechanisms behind carbapenem resistance and the antibiotic management for severe infections caused by key carbapenem-resistant gram-negative bacteria, specifically Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa. For Enterobacterales, it highlights the relative advantages of meropenem-vaborbactam and imipenem-relebactam in treating Klebsiella pneumoniae carbapenemase (KPC)-producing strains with resistance to ceftazidime-avibactam, the preference for ceftazidime-avibactam in addressing oxacillin-hydrolyzing carpapenemase (OXA)-48-like -producing organisms, and the combination of ceftazidime-avibactam with aztreonam for metallo-β-lactamase (MBL)-producing Enterobacterales. Regarding A baumannii, sulbactam-durlobactam is identified as the preferred treatment, while ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam are viable options for P aeruginosa. Additionally, cefiderocol is presented as an alternative for MBL-producing carbapenem-resistant gram-negative bacteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsGram-Negative Bacterial InfectionsDrug Resistance, Multiple, BacterialCarbapenemsGram-Negative BacteriaHumansDrug CombinationsPseudomonas aeruginosa

Stichwörter der Autor:innen

AcinetobacterbaumanniiCarbapenem-resistant EnterobacteralesCarbapenemase-producing EnterobacteralesCarbapenemsCefiderocolMetallo-β-lactamasePseudomonasaeruginosaβ-lactam/β-lactamase inhibitors

Substanzen

Anti-Bacterial AgentsCarbapenemsDrug Combinations

Autor:innen und Institutionen

  • Geriatrics Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, OH, USA; Department of Medicine, Division of Infectious Diseases, Case Western Reserve University, Cle…
  • Geriatrics Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, OH, USA; CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (CARES), Case Wester…
  • Department of Medicine, Division of Infectious Diseases, Case Western Reserve University, Cleveland, OH, USA; CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (CARES), Case Western Reserve Univer…

Förderung

  • Merck

Zitieren

APA

Perez, F., El Chakhtoura, N. G., & Bonomo, R. A. (2025). Management of Severe Infections. Medical Clinics of North America, 109(3), 735-747. https://doi.org/10.1016/j.mcna.2025.01.003

Vancouver

Perez F, El Chakhtoura NG, Bonomo RA. Management of Severe Infections. Medical Clinics of North America. 2025;109(3):735-747. doi:10.1016/j.mcna.2025.01.003

BibTeX
@article{Perez2025,
  author = {Perez, Federico and El Chakhtoura, Nadim G and Bonomo, Robert A},
  title = {Management of Severe Infections},
  journal = {Medical Clinics of North America},
  year = {2025},
  volume = {109},
  number = {3},
  pages = {735--747},
  doi = {10.1016/j.mcna.2025.01.003}
}
Kostenlos starten →